You First Services Awarded Federal Supply Schedule Contract Glotran® Available To US FED Agencies
GloTran® Disinfection Technology Gives Veteran Affairs (VA) Medical Facilities Access To A Powerful Tool To Reduce Hospital-Acquired Infections
The five-year contract, effective Nov. 1, 2021, through Oct. 31, 2026, allows federal customers to easily purchase GloTran, an automated, disinfection system developed by YFS, that utilizes vaporized hydrogen peroxide gas plasma technology to disinfect equipment and materials in a variety of medical and industrial settings.
"Our Company is proud to support and contribute to our government's health care programs," said Sean Dwyer, Marketing Director at YFS. "Our company is committed to improving the quality of life for our nation's veterans and military personnel. Through the VA schedule contract, we can now streamline the procurement process and help government agencies concentrate on the immediate need to prevent Hospital-Acquired Infections by adding GloTran disinfection technology in their healthcare facilities."
The GSA establishes long-term, government-wide contracts with commercial companies. As a pre-approved vendor, YFS extends numerous benefits, including cost-effectiveness, to various agencies and branches of the federal government, as well as state and local governments through its expanding line of medical devices, services, training, and educational programs.
Federal, state, and local agencies can obtain information about YFS' Federal Supply Schedule (FSS) Contract 36F79722D0010¹
ABOUT DEPARTMENT OF VETERANS AFFAIRS FEDERAL SUPPLY SCHEDULE
Under delegated authority by GSA, the VA manages multiple award contracts for medical equipment, supply, pharmaceutical, and service schedule programs. With over $14 billion in sales, the VA FSS Service supports the healthcare requirements of the VA and other federal government agencies by providing Federal customers with access to over 1 million state-of-the-
ABOUT YOU FIRST SERVICES, INC.
You First Services, Inc. was established in May 2013 to acquire and commercialize unique, healthcare-related technologies with high market potential. These technologies have been successfully developed in a research laboratory setting, and have been subject to a full evaluation for commercial value potential regarding formulation development, stability and safety testing, clinical trial completion, regulatory review, product manufacturing scalability, and product marketability.
Director of Sales and Business Development
Page Updated Last on: Jan 26, 2022